Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Tiziana Life Sciences Ltd (TLSA)

Tiziana Life Sciences Ltd (TLSA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 83,372
  • Shares Outstanding, K 97,306
  • Annual Sales, $ 0 K
  • Annual Income, $ -26,130 K
  • 60-Month Beta 1.21
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.54
Trade TLSA with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 04/02/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 297.95% ( -201.57%)
  • Historical Volatility 94.08%
  • IV Percentile 71%
  • IV Rank 19.70%
  • IV High 1,131.31% on 12/14/21
  • IV Low 93.53% on 06/23/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 8
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 479
  • Open Int (30-Day) 454

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/22
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7070 +27.30%
on 05/11/22
1.0500 -14.29%
on 04/29/22
-0.0499 (-5.25%)
since 04/14/22
3-Month
0.5301 +69.78%
on 02/24/22
1.3800 -34.78%
on 03/23/22
+0.1831 (+25.54%)
since 02/17/22
52-Week
0.5301 +69.78%
on 02/24/22
2.8400 -68.31%
on 06/17/21
-1.3800 (-60.53%)
since 05/17/21

Most Recent Stories

More News
Tiziana Life Sciences to participate in a Fireside Chat At the B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference

NEW YORK, April 26, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (NASDAQ: TLSA) ("Tiziana" or the "Company"), a clinical-stage biopharmaceutical...

TILS.LN : 58.500 (+8.33%)
TLSA : 0.9000 (+5.04%)
LTUM Stock Alert: Why Is Lithium Corporation Stock Up Today?

After a false report, multiple sources have confirmed Tesla is not acquiring the lithium miner

TLSA : 0.9000 (+5.04%)
LTUM : 0.2600 (-4.38%)
TWTR : 38.32 (+2.49%)
Tiziana Announces Initiation of Phase 1b Clinical Trial in Crohn’s Disease Patients to Evaluate Oral Capsules of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody

This clinical trial, the first-ever oral immunotherapy for patients with mild-to-moderately active Crohn's Disease, is anticipated to be completed by Q4,...

TILS.LN : 58.500 (+8.33%)
TLSA : 0.9000 (+5.04%)
Tiziana Announces Availability of March 14 KOL Event Replay

NEW YORK, March 15, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling...

TILS.LN : 58.500 (+8.33%)
TLSA : 0.9000 (+5.04%)
Tiziana Life Sciences Hosting Key Opinion Leader Virtual Event to Discuss the Intranasal Delivery of Foralumab in Multiple Sclerosis

Monday, March 14th @ 11 am ET, registration details below...

TILS.LN : 58.500 (+8.33%)
TLSA : 0.9000 (+5.04%)
Top Penny Stocks Today: Why PT, TLSA, AGRI and HTCR Are Up Thursday

Recent announcements are pushing some penny stocks higher

TLSA : 0.9000 (+5.04%)
AGRI : 2.68 (-3.25%)
PT : 1.7000 (-0.58%)
HTCR : 1.2000 (-1.64%)
StemPrintER Demonstrates Prognostic Utility in TransATAC Cohort

NEW YORK, March 01, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd.’s (Nasdaq: TLSA) former subsidiary, AccuStem Sciences, Inc. (OTC PINK: ACMSY)...

TILS.LN : 58.500 (+8.33%)
TLSA : 0.9000 (+5.04%)
ACMSY : 0.1300 (-7.14%)
Tiziana Life Sciences CEO to Present at Annual BIO CEO & Investor Conference

NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling...

TILS.LN : 58.500 (+8.33%)
TLSA : 0.9000 (+5.04%)
Tiziana Announces Submission of Amendment to Investigational New Drug Application to Advance Oral Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, in Patients with Crohn’s Disease

- Tiziana is Developing the First Oral Form of Foralumab in a Convenient Capsule to be Evaluated in Phase 1b Clinical Study NEW YORK, Feb. 04, 2022 ...

TILS.LN : 58.500 (+8.33%)
TLSA : 0.9000 (+5.04%)
Tiziana Life Sciences to participate in a Fireside Chat At the B. Riley Securities 2022 Oncology Conference

NEW YORK, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (NASDAQ: TLSA) ("Tiziana" or the "Company"), a clinical-stage biopharmaceutical...

TILS.LN : 58.500 (+8.33%)
TLSA : 0.9000 (+5.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Tiziana Life Sciences PLC is a biotechnology company. It focuses on the clinical development for the treatment of cancers, chronic inflammatory and autoimmune neurodegenerative disorders. The company's product pipeline consists of Foralumab TZLS-401 and Milciclib TZLS-201 which are in clinical stage....

See More

Key Turning Points

3rd Resistance Point 0.9774
2nd Resistance Point 0.9345
1st Resistance Point 0.8957
Last Price 0.9000
1st Support Level 0.8140
2nd Support Level 0.7711
3rd Support Level 0.7323

See More

52-Week High 2.8400
Fibonacci 61.8% 1.9576
Fibonacci 50% 1.6851
Fibonacci 38.2% 1.4125
Last Price 0.9000
52-Week Low 0.5301

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar